BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38289706)

  • 1. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
    Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
    Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
    Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
    Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
    Zhang B; Zhao W; Li H; Chen Y; Tian H; Li L; Zhang L; Gao C; Zheng J
    Cancer Immunol Immunother; 2016 Mar; 65(3):305-14. PubMed ID: 26842126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells.
    Okumura G; Iguchi-Manaka A; Murata R; Yamashita-Kanemaru Y; Shibuya A; Shibuya K
    J Exp Med; 2020 Mar; 217(4):1. PubMed ID: 32040157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
    Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
    PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
    Cho MM; Song L; Quamine AE; Szewc F; Shi L; Erbe AK; Ebben JD; Turicek DP; Kline JM; Burpee DM; Lafeber EO; Phillips MF; Ceas AS; Capitini CM
    bioRxiv; 2024 Jun; ():. PubMed ID: 37333207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
    J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells.
    Mantovani S; Varchetta S; Mele D; Maiello R; Donadon M; Soldani C; Franceschini B; Torzilli G; Tartaglia G; Maestri M; Piccolo G; Barabino M; Opocher E; Bernuzzi S; Mondelli MU; Oliviero B
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
    Lupo KB; Matosevic S
    J Hematol Oncol; 2020 Jun; 13(1):76. PubMed ID: 32532329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
    Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
    Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
    Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
    J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of inhibitory receptor TIGIT to NK cell education.
    He Y; Peng H; Sun R; Wei H; Ljunggren HG; Yokoyama WM; Tian Z
    J Autoimmun; 2017 Jul; 81():1-12. PubMed ID: 28438433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.
    Fionda C; Abruzzese MP; Zingoni A; Soriani A; Ricci B; Molfetta R; Paolini R; Santoni A; Cippitelli M
    BMC Cancer; 2015 Jan; 15():17. PubMed ID: 25609078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.
    Wang D; Gu Y; Yan X; Huo C; Wang G; Zhao Y; Teng M; Li Y
    Front Oncol; 2022; 12():844260. PubMed ID: 35433470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4
    Kamrani A; Soltani-Zangbar MS; Shiri S; Yousefzadeh Y; Pourakbari R; Aghebati-Maleki L; Mehdizadeh A; Danaii S; Jadidi-Niaragh F; Yousefi B; Kafil HS; Hojjat-Farsangi M; Motavalli R; Zolfaghari M; Haji-Fatahaliha M; Mahmoodpoor A; Ahmadian Heris J; Emdadi A; Yousefi M
    Immunol Invest; 2022 May; 51(4):1023-1038. PubMed ID: 33855917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.